Generate Biomedicines (NASDAQ:GENB) Stock Price Up 4.9% – Time to Buy?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) traded up 4.9% on Tuesday . The company traded as high as $16.35 and last traded at $16.4660. Approximately 57,607 shares changed hands during trading, a decline of 91% from the average session volume of 657,916 shares. The stock had previously closed at $15.69.

Analyst Ratings Changes

A number of equities research analysts have commented on GENB shares. HC Wainwright raised their target price on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Weiss Ratings initiated coverage on shares of Generate Biomedicines in a research note on Tuesday, August 11th. They set a “sell (d)” rating on the stock. Wall Street Zen downgraded shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Morgan Stanley raised their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Generate Biomedicines has an average rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Trading Up 5.5%

The stock has a market cap of $2.18 billion and a price-to-earnings ratio of -10.67. The firm has a fifty day moving average of $14.83.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $6.31 million during the quarter. On average, sell-side analysts anticipate that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Generate Biomedicines stock. Bank of New York Mellon Corp acquired a new position in Generate Biomedicines Inc (NASDAQ:GENB) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 57,326 shares of the company’s stock, valued at approximately $967,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.